VAERS reports by lot

GSK DTaP/Tdap lot 25A2F: VAERS reports

23 VAERS reports list lot 25A2F as a GSK DTaP/Tdap vaccine, received between 2023-10-03 and 2024-10-16. Data: VAERS public files through 31 December 2024 (site extract 2026-07-04).

Read this first. VAERS accepts reports from anyone, and a report does not establish that the vaccine caused the event. A lot's report count mostly reflects how many doses it contained, when it was used and who received it; no administered-dose counts are published for this lot, so counts are not rates and cannot rank lots against each other. Lot numbers in VAERS reports are typed by reporters and are sometimes wrong.
23
Reports
0%
Marked serious
0
With a death outcome
10
Months with reports

Symptom categories in these reports

A report can mention several categories, so the counts add up to more than the number of reports.

CategoryCount%
Neurological721%
Cardiac / Cardiovascular721%
Musculoskeletal412%
Injection-site / Local reaction412%
Allergic / Anaphylactic39%
Gastrointestinal39%
Dermatological (non-injection-site)26%
General / Systemic (non-local)26%
Respiratory13%

Where reports came from

U.S. state of the reporter, where given (top 12).

New York4
North Carolina3
Wisconsin3
Michigan2
Texas2
Georgia2
Colorado2
Arkansas1
Iowa1
Florida1
Indiana1
Maryland1

Reports by month received

2023-104
2023-112
2023-122
2024-023
2024-031
2024-044
2024-051
2024-062
2024-071
2024-103

Products recorded with this lot

Manufacturer and product as reported in VAERS. Reports listing the lot under more than one product are counted once.

Related

Source: VAERS public data (CDC/FDA), grouped by manufacturer and lot by the Open Source Medicine Foundation; extract 2026-07-04 16:35 UTC. Not medical advice. Report errors via contact.